5-氨基-4-甲基皮考啉腈 | 897733-08-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氨基-4-甲基皮考啉腈
• 英文名称: 5-Amino-4-methylpicolinonitrile
• 英文别名: 5-amino-4-methylpyridine-2-carbonitrile
• CAS: 897733-08-3
• 化学式: C₇H₇N₃
• 分子量: 133.15
• InChiKey: QXMRBIGIIPVYGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(6-chloro-5-methoxy-pyrimidin-4-yloxy)-piperidine-1-carboxylic acid isopropyl ester 、 5-氨基-4-甲基皮考啉腈 、 2,8,9-三异丁基-2,5,8,9-四氮杂-1-磷酸双向环[3.3.3]十一烷 、 sodium t-butanolate 在 醋酸钯 乙酸乙酯 、 magnesium sulfate 、 SiO2 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 以to afford isopropyl 4-(6-(6-cyano-4-methylpyridin-3-ylamino)-5-methoxypyrimidin-4-yloxy)piperidine-1-carboxylate in 31% (102 mg)的产率得到Isopropyl 4-(6-(6-cyano-4-methylpyridin-3-ylamino)-5-methoxypyrimidin-4-yloxy)piperidine-1-carboxylate
  参考文献：
  名称：

  Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

  摘要：

  本发明涉及某些取代的吡啶基和嘧啶基衍生物，其化学式为(Ia)，它们是代谢调节剂。因此，本发明的化合物在代谢相关疾病及其并发症的治疗中是有用的，例如糖尿病和肥胖症。

  公开号：

  US20070078150A1
• 作为产物：
  描述：

  2-氰基-4-甲基-5-硝基吡啶 、 乙酸乙酯 在 锌 magnesium sulfate 、 乙酸乙酯 、 正己烷 作用下， 以 氯化铵 为溶剂， 反应 3.5h， 以to give 5-amino-4-methylpicolinonitrile in 67% (4.56 g)的产率得到5-氨基-4-甲基皮考啉腈
  参考文献：
  名称：

  Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

  摘要：

  本发明涉及某些Formula（Ia）的取代吡啶基和嘧啶基衍生物，它们是代谢调节剂。因此，本发明的化合物在治疗代谢相关疾病及其并发症，如糖尿病和肥胖症方面是有用的。

  公开号：

  US20060155128A1

文献信息

• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2017012647A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds according to Formula (I), wherein R1, R3, R4, R5, L1, and Cy are as defined herein. The present invention also provides compounds, methods for the production of said compounds of the invention, pharmaceutical compositions comprising the same and their use in allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 and/or interferons. The present invention also methods for the prevention and/or treatment of the aforementioned diseases by administering a compound of the invention.

  本发明公开了根据式（I）的化合物，其中R1、R3、R4、R5、L1和Cy如本文所定义。本发明还提供了该发明的化合物、制备该化合物的方法、包括相同化合物的药物组合物以及它们在过敏或炎症症状、自身免疫疾病、增殖性疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形和/或与IL6和/或干扰素过度分泌相关的疾病中的使用。本发明还提供了通过给予该发明的化合物来预防和/或治疗上述疾病的方法。
• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2019076716A1

  公开（公告）日：2019-04-25

  The present invention discloses compounds according to Formula I: (Formula I) Wherein R1, L1, R2, L2, R3, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.

  本发明公开了根据式I的化合物：（式I）其中R1，L1，R2，L2，R3，Cy和下标n如本文所定义。本发明涉及化合物、其生产方法、包括其在内的药物组合物，以及使用这些化合物进行预防和/或治疗过敏性疾病、炎症性疾病、代谢性疾病、自身炎症性疾病、自身免疫性疾病、增殖性疾病、移植排斥、涉及软骨周转受损、先天软骨畸形和/或与IFNα、IL12和/或IL23过度分泌相关的疾病的治疗方法。
• NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：MENET Christel Jeanne Marie

  公开号：US20150203455A1

  公开（公告）日：2015-07-23

  The present invention discloses compounds according to Formula I: wherein Cy, R 1 , L 1 , R 3 , R 4 , R 5 , L a , and R a are as defined herein. Novel benzimidazoles according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons.

  本发明公开了根据以下公式I的化合物：其中Cy、R1、L1、R3、R4、R5、La和Ra如本文所定义。根据公式I的新型苯并咪唑，能够抑制JAK，这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，包括但不限于过敏性疾病、炎症性疾病、自身免疫性疾病、增殖性疾病、移植排斥反应、涉及软骨周转障碍的疾病、先天性软骨畸形以及与IL6过度分泌或干扰素过度分泌相关的疾病。
• [EN] BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2015110378A1

  公开（公告）日：2015-07-30

  The present invention discloses compounds according to Formula (I) wherein Cy, R1, L1 R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula (I), able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons.

  本发明公开了根据式(I)的化合物，其中Cy、R1、L1、R3、R4、R5、La和Ra如本文所定义。公开了根据式(I)的能够抑制JAK的新型苯并咪唑类化合物，这些化合物可以制备成药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，包括但不限于过敏性疾病、炎症性疾病、自身免疫性疾病、增生性疾病、移植排斥、涉及软骨代谢障碍的疾病、先天性软骨畸形以及与IL6或干扰素过度分泌相关的疾病。
• Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
  申请人：Jones M. Robert

  公开号：US20070078150A1

  公开（公告）日：2007-04-05

  The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

  本发明涉及某些取代的吡啶基和嘧啶基衍生物，其化学式为(Ia)，它们是代谢调节剂。因此，本发明的化合物在代谢相关疾病及其并发症的治疗中是有用的，例如糖尿病和肥胖症。